Skip to content

Aclaris Therapeutics ACRS Contract Liabilities

Contract Liabilities at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$0
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$979K-94.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$79M-72.9%
Alumis Inc. logo
Alumis Inc.ALMS
$2.61M
Janux Therapeutics logo
Janux TherapeuticsJANX
$8.68M
Kura Oncology logo
Kura OncologyKURA
$416.75M+53.3%

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%
P/S82×+73.1×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's contract liabilities?
Aclaris Therapeutics (ACRS) reported contract liabilities of $15.29M in Q1 2026.
How has Aclaris Therapeutics's contract liabilities changed year-over-year?
Aclaris Therapeutics's contract liabilities decreased by 20.4% year-over-year, from $19.21M to $15.29M.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.